Share Name Share Symbol Market Type Share ISIN Share Description
Cellular Goods Plc LSE:CBX London Ordinary Share GB00BK964W87 ORD GBP0.001
  Price Change % Change Share Price Shares Traded Last Trade
  0.475 6.76% 7.50 5,150,060 16:35:05
Bid Price Offer Price High Price Low Price Open Price
7.00 7.50 7.35 6.875 7.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Personal Goods 38
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:04 O 200,000 7.20 GBX

Cellular Goods (CBX) Latest News

More Cellular Goods News
Cellular Goods Investors    Cellular Goods Takeover Rumours

Cellular Goods (CBX) Discussions and Chat

Cellular Goods Forums and Chat

Date Time Title Posts
17/6/202115:09Cellular goods consumer cannabis976
04/6/202109:05CBX with Charts & News1
17/5/202106:36Share Tip Buddy -
26/4/202115:56New gambling stock126

Add a New Thread

Cellular Goods (CBX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-17 16:16:267.20200,00014,400.00O
2021-06-17 16:15:006.58607,48539,972.51O
2021-06-17 16:06:147.28200,00014,554.00O
2021-06-17 15:45:117.30250,00018,237.50O
2021-06-17 15:44:367.00300,00021,000.00O
View all Cellular Goods trades in real-time

Cellular Goods (CBX) Top Chat Posts

Cellular Goods Daily Update: Cellular Goods Plc is listed in the Personal Goods sector of the London Stock Exchange with ticker CBX. The last closing price for Cellular Goods was 7.03p.
Cellular Goods Plc has a 4 week average price of 6.10p and a 12 week average price of 6.10p.
The 1 year high share price is 27.50p while the 1 year low share price is currently 6.10p.
There are currently 504,750,000 shares in issue and the average daily traded volume is 2,231,924 shares. The market capitalisation of Cellular Goods Plc is £37,856,250.
kirk 6: Multiyear supply agreement for cannabigerol (CBG) signed with Willow BiosciencesCellular Goods (LSE: CBX), a UK-based provider of premium consumer products based on lab-made cannabinoids, and Willow Biosciences Inc. ("Willow") (TSX: WLLW; OTCQX: CANSF), a biotechnology company producing ultra-pure, sustainably made compounds, are pleased to announce they have signed a multiyear supply agreement whereby Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' premium cannabinoid-based skin care products which launch in the autumn of 2021.Willow's first shipment of Willow CBG to Cellular Goods will arrive in July this year.In April 2021, Willow announced the completion of a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow CBG on human skin. These results, coupled with the sustainable and safe manufacturing nature of Willow's manufacturing process, make Willow CBG an ideal core ingredient for cosmetics in the evolving regulatory landscape of the United Kingdom.Last month the European Commission declared that cannabigerol (CBG) had been added to the EU cosmetic ingredients database (named "CosIng"), approving the compound as safe for use in personal care and cosmetics products. European manufacturers of personal care and cosmetics products can now use CBG in their products with the approval of a major market regulator for trade in the European Union. At present, the UK remains harmonised with CosIng.Alexis Abraham, Cellular Goods' Chief Executive Officer, said: "Successful products start with the best ingredients and being able to source consistent, highly-pure cannabinoids via cellular agriculture from a trusted provider like Willow is essential to our business. CBG is the most promising cannabinoid for skincare applications and we believe it will become a must have upgrade to people's daily routines. Cellular Goods will be the first to bring a range to market in the UK built on our core principles of delivering efficacy-led and research-backed consumer cannabinoid products."Trevor Peters, Willow's President & Chief Executive Officer, said: "We are very excited to announce our first commercial supply agreement for CBG. In just over two years we have gone from proof of concept in the lab to commercial scale up and sales of our first cannabinoid which will be slated for use in a consumer product. Cellular Goods are at the forefront of developing premium consumer cannabinoid products in the United Kingdom and we are thrilled to be supplying them with our ultra-pure, biosynthetically made CBG."
noirua: Subject of course to sudden news from the company. The share price of CBX should lift. There is a point on the chart indicating the next stopping point at 7.8p - 8.6p.
noirua: CBX are probably at or near their lowest point. May prove to have been oversold.
intelinvestor: Without any revenue, it’s difficult to judge the level of demand for its products or how sticky they will be with customers. To me, there are a lot of unknowns, and an unprofitable business with no existing revenue sources is quite a risky investment. Perhaps the realisation of this is why the Cellular Goods share price has been falling over the past few weeks.
ianpaulrose: From research, I understand that Zoetic's (Zoe) CBD "Chill brands" are now selling in Smokers Friendly 852 stores Normally a standard convenience store would sell 7-10 packs of "Chill" cigarettes and chews per day at a profit of $3.50 per pack so annual profit per store based on 7 packs per day would be $8,600 Smokers Friendly stores sell 10 x more product than these standard convenience store so they will sell 70 packs a day making $86,000 profit per store per year Over the 852 stores this means annual profit to Zoetic of c$73 million once fully rolled out in a couple of years If we assume a conservative multiple of after tax profits of 25, this means just these incremental sales are worth $1.5 billion of shareholder value As Zoetic has 190 million shares in issue this alone should be worth roughly an additional £6 a share ($8) to the current share price !
duxy786: FPP have nothing material and there is nothing to indicate they can even get a share in anything material as yet, however, the share price is already overpriced by the hype created on twitter / forums as can be seen by the previous posts here.Just trying to create a balanced view. No advice intended.
alexios1201: Fragrant Prosperity: financial services SPAC looks like it is going hunting for cannabis opportunitiesIts announced intention to make a cannabis investment has sent shares of shell company Fragrant Prosperity (LON:FPP) soaring and given the potential in this sector, this makes it a SPAC (special purpose acquisition company) to follow closely.In late February, shares rose more than 40 % to a high of 6.85p after the company issued a statement that it was eyeing the medicinal cannabis and CBD wellness sectors in addition to its original plan to look for opportunities in the financial services sector.Focus on cannabis and cannabis therapeuticsOn March 3, Fragrant made a share placement, raising £543,930 to provide additional capital for the company to pursue its investment strategy, "in particular" said chair Craig J. Marshak in the cannabis and cannabis therapeutics sectors. So almost definitely shelving financial services for now.Fragrant Prosperity also announced it expected to appoint "in the reasonably near future at least one additional director who will add to the current in depth experience of the existing board to assist with this search". It also appointed UK counsel with experience of cannabis business listing.It's not hard to see why a SPAC that was set up in 2017 but has yet to find a suitable acquisition in its initial target sector would look at this burgeoning cannabis sector which is expected to reach $73.6 billion by 2027 globally.The shift in strategy follows guidance issued by the Financial Conduct Activity on admission of medicinal cannabis and CBD oil companies to the Official list and the subsequent IPOs by Israel's Kanabo Group (LSE:KNB) and MGC Pharmaceuticals (LSE:MXC).Fragrant said that as a result it had been presented with "a number of investment opportunities" in this area and that it is considering a number of opportunities although it added that discussions are at a very early stage.Of SPACs and cannabis opportunitiesShares in various cannabis related stocks have seen some sharp rises in recent times. Kanabo, which also listed via a SPAC, was up 500% last week from its initial offer price while MGC spiked sharply a few days ago on news of an increased purchase order for one of its products.Exchange traded funds active in this sector have also been posting some impressive gains. Seven of the top 10 best-performing funds were active in this field, according to data from TrackInsight.Then there is the shift in the regulatory regime with the election of Joe Biden in the US paving the way for further acceptance and approval of cannabis related products and the UN's removal of cannabis from the convention on narcotic drugs, giving a further boost to what we have dubbed Cannabis 2.0, the second wave in the development of the sector.For Fragrant Prosperity, much will depend of course on which company it acquires. In a sector that is becoming increasingly populated and where some forecasters expect to see a drop in the cannabis price, not every company offers the same potential for investors.We prefer those with some geographical diversification and which can therefore take full advantage of markets with more favourable regulatory regimes. If Fragrant Prosperity can find an opportunity that ticks those boxes, we can expect to see some interesting developments in its share price
gordan ghetto: The best cannabis stock in the UK Will be producing 200 TONS which is worth £400m. Current mkt cap £6.4m 50# of shares not in open market BOD own 30% Have GW Pharmas growers (GW just got sold for £7b) ANA has the most land (30-50 hectares) out of all the cannabis stocks They will be no 1 in the UK just like Canopy Growth is in USA Current share price 1.08p hTTps:// hTTps:// I would take a position if I was you
cottoner: Not sure why its showing 83% up rather than increase from IPO share price. Presumably because the price is 83% up on the final price of the last company Cubus Lux which used CBX and was delisted from AIM in 2012.
sif12: youd hope with derampers they can at least use a calculator. shares cant go into an ISA. Not sure why its showing 83% up rather than increase from IPO share price
Cellular Goods share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Cellular G..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 03:51:04